A new approach against sugar cataract through aldose reductase inhibitors

Experimental Eye Research

Volumn 69, Issue 5, 1999, Pages 533-538

  Banditelli, Stefania ^a   Boldrini, Enrico ^b   Vilardo, Pier Giuseppe ^a   Cecconi, Ilaria ^a   Cappiello, Mario ^a   Dal Monte, Massimo ^a   Marini, Isabella ^a   Del Corso, Antonella ^a   Mura, Umberto ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Farmigea SpA   (Italy)

Author keywords

Aldose reductase inhibitors; Diabetic cataract; Drug delivery; Lens; Tolrestat

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; GALACTITOL; GALACTOSE; TOLRESTAT;

ANIMAL MODEL; ARTICLE; CATARACT; CATARACTOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0032730809     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1006/exer.1999.0729     Document Type: Article

References (32)

1. Ao S., KiKuchi C., Ono T., Natsu Y. Effect of instillation of aldose reductase inhibitor FR74366 on Diabetic Cataract. Invest. Ophthalmol. Vis. Sci. 32:1991;3078-3083.
2. Barsacchi D., Cappiello M., Tozzi M. G. et al. Purine nucleoside phosphorylase from bovine lens: purification and properties. Biochim. Biophys. Acta. 1160:1992;163-170.
3. Baynes J. W. Role of oxidative stress in the development of complications in diabetes. Diabetes. 40:1991;405-412.
4. Beyers-Mears A., Kelly K., Cruz E. Synergism of Sorbinil and normal diet on reversal of stage-II sugar cataract. Pharmacology. 31:1985;170-179.
5. Beyers-Mears A., Mistry K., Diecke F. P. J., Cruz E. Zopolrestat prevention of proteinuria, albuminuria, and cataractogenesis in diabetes mellitus. Pharmacology. 52:1996;292-302.
6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizating the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
7. Cappiello M., Voltarelli M., Giannessi M. et al. Glutathione dependent modification of bovine lens aldose reductase. Exp. Eye Res. 58:1994;491-501.
8. Crabbe M. J. C., Goode D. Aldose reductase: a window to the treatment of diabetic complications? Prog. Retinal Eye Res. 17:1998;313-383.
9. Dal Monte M., Cecconi I., Buono F., Vilardo P. G., Del Corso A., Mura U. Thioltransferase activity of bovine lens glutathione S-transferase. Biochem. J. 334:1998;57-62.
10. Datiles M., Fukui H., Kuwabara T., Kinoshita J. H. Galactose cataract prevention with Sorbinil, an aldose reductase inhibitor: a light microscopic study. Invest. Ophthalmol. Vis. Sci. 22:1982;174-179.
11. Del Corso A., Barsacchi D., Giannessi M., et al. Bovine lens aldose reductase: tight binding of the pyridine coenzyme. Arch. Biochem. Biophys. 283:1990;512-518.
12. Dvornik D., Simard-Duquesne N., Krami M., et al. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science. 182:1973;1146-1148.
13. Jiang Z. Y., Zhou Q. L., Eaton J. W., Koppenol W. H., Hunt J. V., Wolff S. P. Spirohydantoin inhibitors of aldose reductase inhibit iron- and copper-catalysed ascorbate oxidation in vitro. Biochem. Pharmacol. 42:1991;1273-1278.
14. Jones R. H. V., Hotehersall J. S. The effect of diabetes and dietary ascorbate supplementation on the oxidative modification of rat lens βL-crystallins. Biochem. Med. Metabol. Biol. 50:1993;197-209.
15. Kinoshita J. H. Mechanism initiating cataract formation. Invest. Ophthalmol. Vis. Sci. 13:1974;713-724.
16. Krans H. M. J. Recent clinical experience with aldose reductase inhibitors. J. Diabetes Complications. 6:1992;39-44.
17. Lee A. Y., Chung S. K., Chung S. S. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. Proc. Natl. Acad. Sci. USA. 92:1995;2780-2784.
18. Linklater H. A., Dzialoszynski T., McLeod H. L., Sanford S. E., Trevithick J. R. Modelling cortical cataractogenesis VIII: effects of butylated hydroxytoluene (BHT) in reducing protein leakage from lens in diabetic rats. Exp. Eye Res. 43:1986;305-313.
19. Manius G., Mahn F. P., Venturella V. S., Senkowski B. Z. GLC determination of sorbitol and mannitol in aqueous solutions. J. Pharm. Sci. 61:1972;1831-1835.
20. Marini I., Bucchioni L., Borella P., Del Corso A., Mura U. Sorbitol dehydrogenase from bovine lens: purification and properties. Arch. Biochem. Biophys. 340:1997;383-391.
21. Raskin P. Aldose reductase inhibitors - hope or hype. J. Diabetes Complications. 6:1992;69.
22. Robison W. G. Jr, Nagata M., Laver N., Hohman T. C., Kinoshita J. H. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest. Ophthalmol. Vis. Sci. 30:1989;2285-2292.
23. Sarges R., Oates P. J. Aldose reductase inhibitors: recent developments. Prog. Drug Res. 40:1993;99-161.
24. Sato S., Mori K., Wyman M., Kador P. F. Dose-dependent prevention of sugar cataract in galactose fed dogs by the aldose reductase inhibitor M79175. Exp. Eye Res. 66:1998;217-222.
25. Sorbinil Retinopathy Trial Research Group. A randomized trial of Sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch. Ophthalmol. 108:1990;1234-1244.
26. Srivastava S., Chandra A., Bhatnagar A., Srivastava S. K., Ansari N. H. Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem. Biophys. Res. Commun. 217:1995;741-746.
27. Stevens V. J., Rouzer C. A., Monnier V. M., Cerami A. Diabetic cataract formation: potential role of glycosylation of lens crystallins. Proc. Natl. Acad. Sci. USA. 75:1978;2918-2922.
28. Tomlinson D. R., Willars G. B., Carrington A. L. Aldose reductase inhibitors and diabetic complications. Pharmac. Ther. 54:1992;151-194.
29. Unakar N. J., Tsui J. Y., Johnson M. J. Effect of aldose reductase inhibitors on lenticular dulcitol level in galactose fed rats. J. Ocular Pharmacol. 8:1992;199-212.
30. Vander Jagt D. L., Kolb N. S., Vander Jagt T. J. et al. Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as endogenous substrate. Biochim. Biophys. Acta. 1249:1995;117-126.
31. Varma S. D., Kinoshita J. H. The absence of cataracts in mice with congenital hyperglycemia. Exp. Eye Res. 19:1974;577-582.
32. Wolff S. P., Crabbe M. J. Low apparent AR2 activity produced by monosaccharide autoxidation. Biochem. J. 226:1985;625-630.